welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
study id #: NCT03532542
condition: Duchenne Muscular Dystrophy
status: enrolling by invitationpurpose:
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
intervention: Casimersen, Golodirsen
mechanism of action: Exon-skipping to promote dystrophin production
last updated: January 07, 2020
start date: August 2, 2018
estimated completion: August 10, 2026
phase of development: Phase 3
size / enrollment: 260
- Number of patients with serious adverse events (SAEs) [Time Frame: Up to 30 days after the last infusion of study drug (assessed up to 148 weeks)]]
• Eligible Sexes: male
• Is between 7 and 23 years of age, inclusive, at enrollment.
Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE StudySarepta Therapeutics, Inc., the leader i...
Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyThis study is a long-term study of atalu...
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyThe study is to demonstrate non-inferior...
Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular DystrophySarepta Therapeutics, Inc., the leader...
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular DystrophyDystrophinopathy is a disease continuum ...
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug ApplicationOn February 14, 2019, Sarepta Therapeuti...
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...